Associated Papers
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
36910641 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S8
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
34788622 (PubMed )
Supplement: NIHMS1757901-supplement-2.xlsx › SNVs_indels
Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations.
Kim IA et al.
Cancers, 2021
34298845 (PubMed )
Supplement: cancers-13-03632-s001.zip › cancers-1262449-supplementary.pdf
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases.
Koivu MKA et al.
Molecular Cancer Therapeutics, 2021
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.
Pleasance E et al.
Nature Cancer, 2020
35121966 (PubMed )
Supplement: 43018_2020_50_MOESM3_ESM.xlsx › Supplementary_Table_5
Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
Tang Y et al.
Journal of Cancer Research and Clinical Oncology, 2020
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
The reliable assurance of detecting somatic mutations in cancer-related genes by next-generation sequencing: the results of external quality assessment in China.
Zhang R et al.
Oncotarget, 2016
Select a paper to view details